유럽의 차세대 IVD 시장 : 분석 및 예측(2023-2033년)

“The Europe Next-Generation IVD Market Expected to Reach $40.41 Billion by 2033.”

Introduction to Europe Next-Generation IVD (In vitro diagnostics) Market

The Europe next-generation IVD market was valued at $24.20 billion in 2023 and is expected to reach $40.41 billion by 2033, growing at a CAGR of 5.26% between 2023 and 2033. The utilization of emerging technologies and innovations in diagnostics has the capacity to stimulate the expansion of the next-generation IVD (In Vitro Diagnostic) market. Molecular diagnostics, genomics, and Next-Generation Sequencing (NGS) are anticipated to be key drivers of this growth, offering fresh opportunities for enhanced disease diagnosis and, consequently, reshaping patient outcomes.

Market Introduction

The Europe Next-Generation IVD (In Vitro Diagnostics) Market is witnessing significant growth and transformation. It encompasses a diverse range of advanced diagnostic technologies and tools that are revolutionizing healthcare practices in the region. Key factors driving this market include the increasing prevalence of chronic diseases, rising demand for personalized medicine, and a growing emphasis on early disease detection and management. Molecular diagnostics, genomics, and Next-Generation Sequencing (NGS) are at the forefront of innovation, enabling healthcare professionals to obtain precise insights into patients' conditions. These technologies offer enhanced accuracy, speed, and efficiency in diagnosing various diseases, including cancer, infectious diseases, and genetic disorders.

Moreover, the Europe market is characterized by robust research and development activities, fostering continuous advancements in IVD solutions. Regulatory support and stringent quality standards ensure the safety and efficacy of these diagnostics. With a focus on improving patient outcomes and optimizing healthcare resources, the Europe Next-Generation IVD Market is poised for continued growth and innovation, contributing to the region's overall healthcare excellence.

Market Segmentation:

Segmentation 1: by Type

• Core Laboratory Diagnostics
• POC Testing
• Molecular Diagnostics

Segmentation 2: by End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Academic and Research Institutions
• Other End Users

Segmentation 3: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The Europe next-generation IVD market has been extensively segmented on the basis of various categories, such as type and end user. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe next-generation IVD market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the Europe next-generation IVD market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Table of Contents

Executive Summary

1. Markets

• 1.1. Market Scope
  • 1.1.1. Key Questions Answered in the Report
• 1.2. Research Methodology
  • 1.2.1. Next-Generation IVD Market: Research Methodology
  • 1.2.2. Data Sources
    • 1.2.2.1. Primary Data Sources
    • 1.2.2.2. Secondary Data Sources
  • 1.2.3. Market Estimation Model
  • 1.2.4. Criteria for Company Profiling

2. Market Overview

• 2.1. Introduction
  • 2.1.1. Next-Generation IVD Market Outlook
    • 2.1.1.1. POC-IVD
    • 2.1.1.2. Diagnostic Expenditures
    • 2.1.1.3. Pricing Patterns of Next-Generation IVD
  • 2.1.2. Market Size and Growth Potential
    • 2.1.2.1. Short-Term Impact (2020-2025)
    • 2.1.2.2. Long-Term Impact (2026-2033)
  • 2.1.3. Product Benchmarking by Next- Generation In-vitro Diagnostics Market, (by Type)
• 2.2. COVID-19 Impact on the Next-Generation IVD Market
  • 2.2.1. Impact on Operations
  • 2.2.2. COVID-19 Impact: Current Scenario of the Market
  • 2.2.3. Pre-COVID Assessment
  • 2.2.4. Post-COVID-19 Market Assessment

3. Industry Analysis

• 3.1. Legal Requirements
  • 3.1.1. Legal Requirements and Framework in Europe

4. Market Dynamics

• 4.1. Overview
• 4.2. Impact Analysis
• 4.3. Market Drivers
  • 4.3.1. Technological Advancements in Next-Generation In-Vitro Diagnostics Transforming Healthcare System
  • 4.3.2. Rising Demand of POC Testing Boosting Next-Generation IVD Market
  • 4.3.3. Growing Incidence of Chronic and Acute Diseases Demanding for Early Treatment
  • 4.3.4. Boost in the Next-Generation IVD Market during COVID-19 Pandemic
• 4.4. Market Challenges
  • 4.4.1. Regulatory Hurdles Related to Next-Generation IVD Technologies
  • 4.4.2. Poor Reimbursement Scenario
• 4.5. Market Opportunities
  • 4.5.1. Rising Number of Next-Generation IVD Companies Involved in Business Expansion
  • 4.5.2. Inclination of Emerging Companies toward Next-Generation IVD

5. Next-Generation IVD Market, by Region, $Million, 2022-2033

• 5.1. Overview
• 5.2. Europe
  • 5.2.1. Market Dynamics
  • 5.2.2. Market Size and Forecast
    • 5.2.2.1. Europe Next-Generation IVD Market (by End User)
    • 5.2.2.2. Europe Next-Generation IVD Market (by Type)
      • 5.2.2.2.1. Europe Next-Generation Core Laboratory IVD Market, (by Type)
    • 5.2.2.3. Europe Next-Generation IVD Market (by Country)
      • 5.2.2.3.1. Germany
        • 5.2.2.3.1.1. Market Size and Forecast
        • 5.2.2.3.1.1.1. Germany Next-Generation IVD Market (by End User)
        • 5.2.2.3.1.1.2. Germany Next-Generation IVD Market (by Type)
      • 5.2.2.3.2. France
        • 5.2.2.3.2.1. Market Size and Forecast
        • 5.2.2.3.2.1.1. France Next-Generation IVD Market (by End User)
        • 5.2.2.3.2.1.2. France Next-Generation IVD Market (by Type)
      • 5.2.2.3.3. U.K.
        • 5.2.2.3.3.1. Market Size and Forecast
        • 5.2.2.3.3.1.1. U.K. Next-Generation IVD Market (by End User)
        • 5.2.2.3.3.1.2. U.K. Next-Generation IVD Market (by Type)
      • 5.2.2.3.4. Italy
        • 5.2.2.3.4.1. Market Size and Forecast
        • 5.2.2.3.4.1.1. Italy Next-Generation IVD Market (by End User)
        • 5.2.2.3.4.1.2. Italy Next-Generation IVD Market (by Type)
      • 5.2.2.3.5. Spain
        • 5.2.2.3.5.1. Market Size and Forecast
        • 5.2.2.3.5.1.1. Spain Next-Generation IVD Market (by End User)
        • 5.2.2.3.5.1.2. Spain Next-Generation IVD Market (by Type)
      • 5.2.2.3.6. Rest-of-Europe
        • 5.2.2.3.6.1. Market Size and Forecast
        • 5.2.2.3.6.1.1. Rest-of-Europe Next-Generation IVD Market (by End User)
        • 5.2.2.3.6.1.2. Rest-of-Europe Next-Generation IVD Market (by Type)

6. Company Profiles

• 6.1. Overview
• 6.2. bioMerieux SA (BioFire Diagnostics)
  • 6.2.1. Company Overview
  • 6.2.2. Role of bioMerieux SA (BioFire Diagnostics) in the Next-Generation IVD Market
  • 6.2.3. Financials
  • 6.2.4. Recent Developments
    • 6.2.4.1. Corporate Strategies
    • 6.2.4.2. Business Strategies
  • 6.2.5. Analyst Perspective
• 6.3. F. Hoffmann-La Roche Ltd. (Roche Molecular Systems, Inc.)
  • 6.3.1. Company Overview
  • 6.3.2. Role of F. Hoffmann-La Roche Ltd. in the Next-Generation IVD Market
  • 6.3.3. Financials
  • 6.3.4. Recent Developments
    • 6.3.4.1. Business Strategies
  • 6.3.5. Analyst Perspective
• 6.4. QIAGEN N.V.
  • 6.4.1. Company Overview
  • 6.4.2. Role of QIAGEN N.V. in the Next-Generation IVD Market
  • 6.4.3. Financials
  • 6.4.4. Recent Developments
    • 6.4.4.1. Corporate Strategies
    • 6.4.4.2. Business Strategies
  • 6.4.5. Analyst Perspective
• 6.5. Siemens Healthineers AG
  • 6.5.1. Company Overview
  • 6.5.2. Role of Siemens Healthineers AG in the Next-Generation IVD Market
  • 6.5.3. Financials
  • 6.5.4. Recent Developments
    • 6.5.4.1. Corporate Strategies
    • 6.5.4.2. Business Strategies
  • 6.5.5. Analyst Perspective